ReviewCurrent rheumatology reports2017
Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?
Review in Current rheumatology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis.Frontiers in immunology · 2024Guideline
- Targeting macrophage-mediated TGF-β/BMP signaling in ankylosing spondylitis: from inflammation to pathological bone formation.Frontiers in immunology · 2026Review
- State-of-the-Art Review on the Treatment of Axial Spondyloarthritis.Medical sciences (Basel, Switzerland) · 2025Review
- Analysis of Cost-Effectiveness of Biologic Therapies in Axial Spondyloarthritis Based on Real-World Data.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis.Scientific reports · 2024Article
- Presence of subclinical inflammation in axial spondyloarthritis patients with NSAID/anti-TNF-α drug-induced clinical remission.Clinical rheumatology · 2022Article
- To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis.RMD open · 2021Review
- Enhanced BMP-2/BMP-4 ratio in patients with peripheral spondyloarthritis and in cytokine- and stretch-stimulated mouse chondrocytes.Arthritis research & therapy · 2020Article
- Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis.Arthritis research & therapy · 2018Observational
- Serum CCL11 level is associated with radiographic spinal damage in patients with ankylosing spondylitis.Rheumatology international · 2018Article
- Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis.Clinical rheumatology · 2018Article
- No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA.RMD open · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewProgressive ankylosis is a feared consequence of long-standing axial spondyloarthritis. We aim to critically review current insights into the effect of therapy, the molecular pathways involved in this process, and to present a model explaining the sequence of events. RECENT
findingsLong-term follow-up data suggest that successful control of inflammation may slow down radiographic progression of disease in axial spondyloarthritis. Structural effects of new therapies such as interleukin-17 targeting need to be further studied. Bone loss and architectural changes could act as driver for the tissue remodeling process trying to maintain spinal stability in the presence of inflammation. Despite some progress, the nature and mechanisms of new bone formation in axial spondyloarthritis still remain incompletely understood. However, long-term control of inflammation appears critical to avoid progressive disability due to structural damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.